SUMMARY Auranofin (SKF-D 39162) is an oral gold preparation for the treatment of rheumatoid arthritis. One of its major side effects is diarrhoea. To determine one possible mechanism for this we compared the effects of auranofin and myochrysine on intestinal water and solute transport in the rat. Jejunal perfusion with 2 mM auranofin (n=5) induced fluid and electrolyte secretion and inhibited glucose absorption (p<0-01). Auranofin (0-2 mM) induced fluid secretion in the jejunum (n=5; p<001) and colon (n=6; p<0O01). In contrast, 2 mM myochrysine enhanced jejunal water and electrolyte absorption (n=6; p<0-02). Both compounds enhanced absorption of mannitol (p<0-01). Perfusion of 0.2 mM auranofin for two hours had no significant effect on mucosal c-AMP levels (n=4). After perfusion for two hours with 2 mM auranofin the jejunal mucosa showed severe injury by light and scanning electronmicroscopy while myochrysine had no apparent effect. The damage after perfusion with 0-2 mM auranofin for two hours was less severe. Auranofin was more rapidly absorbed than myochrysine (p<0.05). These effects provide an explanation for the diarrhoea associated with auranofin therapy.
diarrhoea associated with auranofin therapy.
Auranofin (SKF-D39162) (2,3,4,6 tetra-o-acetyl-
1-thio-3-D-glucopyranosato-S-[triethyl-phospine]-
gold [I] ) is used for oral chrysotherapy of rheumatoid arthritis.`A well recognised side effect of therapy with auranofin is diarrhoea.'-3 The mechanism by which auranofin induces diarrhoea has not been investigated in vivo. Here we report the effects of auranofin on electrolyte and water transport, mucosal permeability and morphology in the rat intestine in comparison with another gold compound, myochrysine (gold-Na-thiomalate).
Methods

MATERIALS
Auranofin was a gift from Smith Kline and French Laboratories, Philadelphia, PA, myochrysine was purchased from Merck-Sharp and Dohme, West- Boston, MA. All compounds were used as purchased. PERFUSION TECHNIQUE In vivo perfusion experiments were carried out in male Sprague-Dawley rats (King Animal Labs, Oregon, WI) weighing 250-350 g. Forty centimetres of proximal jejunum were isolated and cannulated at the proximal and distal ends under general anaesthesia with phenobarbital after an overnight fast. The intestine was rinsed with control solution (as described below) and returned to the abdominal cavity. The lumen was perfused in a single pass at 42 ml/hour. For was statistically significant in the colon (p<001). Auranofin (2mM) inducedwatersecretion (p<0.001) and electrolyte secretion (p<0-05 to p<0-005), reduced the absorption of glucose (p<0005) and enhanced the absorption of mannitol (p<0-01). The fractional absorption of auranofin in the jejunum was 27-8+4-3% during perfusion of 02 mmol/l and 75 8+3 5% during perfusion of 2 mmol/l (p<0-001). Polyethylene glycol recovery was 95-5±1-7% during the control period and 95 1+1 0% during perfusion with 2 mM auranofin (NS).
EFFECTS OF MYOCHRYSINE ON JEJUNAL
TRANSPORT (Table 2) In contrast with auranofin, myochrysine (n=6) enhanced the absorption of water (p<0002), sodium (p<002), and chloride (p<0005). Like auranofin it enhanced the absorption of mannitol (p<0-01). The absorption rate of myochrysine was significantly less than that of auranofin (p<0-001). Polyethylene glycol recovery was 103.6±2*0% during the control period and 109-5+3-4% during the test period (NS).
EFFECT OF AURANOFIN ON MUCOSAL c-AMP (Table 3) Mucosal c-AMP levels were determined after perfusion of 02 mM auranofin. Although auranofin induced water secretion (p<0.01) mucosal c-AMP levels did not differ from those in the control loops.
MORPHOLOGIC STUDIES
Auranofin (2 mM) causes severe mucosal damage characterised by loss of epithelial cells at the villus tips and infiltration with polymorphonuclear leukocytes (not shown). On scanning electron microscopy polymorphonuclear leukocytes and debris covered the villus tips (Figure) . The changes observed after perfusion with 02 mM auranofin appeared less severe, but no morphometric studies were done. In contrast with these findings, the villi appeared intact on light microscopy after perfusion with myochrysine. Scanning electronmicroscopy showed only occasional red blood cells at the tips of the villi.
Discussion
The data indicate that auranofin affects intestinal water transport adversely and that it has the potential to cause mucosal injury. The effect on water transport is dose dependent and present in the small and large bowel. The changes in water movement are associated with net secretion of Na, K, Cl, and bicarbonate, reduction of glucose absorption and enhancement of mannitol absorption. Thus, the effects resemble those of certain dihydroxy bile acids and fatty acids on the intestine.9"' These in vivo observations are in agreement with in vitro studies in the isolated rat intestine, where 0(147 mM auranofin inhibited transport of glycine, galactose, sodium and water."2 The current studies do not provide a definite answer about the mechanism responsible for these changes in intestinal electrolyte and water transport. The data indicate that the secretory effect is not mediated by c-AMP. The inhibition of glucose absorption could be secondary to an effect on active transport of glucose or caused by changes in mucosal permeability. The increased mannitol absorption suggests that mucosal permeability is enhanced by auranofin.3 Recently we have provided evidence which links inhibition of glucose absorption by bile acids to the combined effects of enhancement of mucosal permeability and fluid secretion." Enhancement of mucosal permeability alone, however, does not explain electrolyte and water secretion. Amphotericin B, which also enhances mucosal permeability, stimulates absorption of electrolytes glucose, ethylene glycols, and water in jejunal perfusion experiments." '4 The mechanism by which myochrysine enhanced the intestinal absorption of electrolytes, water and organic solutes remains unknown. The changes in mannitol absorption suggest that enhanced mucosal permeability may be responsible for this phenomenon.
The increase in fractional absorption of auranofin with increasing concentration in the perfusion solution is probably related to the fact that the compound increased mucosal permeability." We cannot, however, exclude the possibility that part of the 'enhanced absorption' may be the result of precipitation of the poorly soluble compound in the test segment during intestinal perfusion because only recovery of the compound in the effluent was determined. It is unlikely that adherence to the mucosa accounts for the observations because in this case one would expect a higher fractional loss of auranofin during perfusion with the solution containing the lower concentration of the compound. In vitro auranofin is absorbed by everted sacs of rat intestine and undergoes deacetylation in the process. '5 The fact that myochrysine is poorly absorbed can be attributed to the greater polarity of this compound and to the fact that it is present in polymer form.36
It is no surprise that auranofin caused mucosal injury because it has cytotoxic effects in tissue culture systems. '7 In long term feeding experiments, auranofin caused gastric erosions and ileocaecal ulcers in rats.'" Thus, the observed injury should not be dismissed as the result of an artificially high concentration of auranofin in a supersaturated solution. Moreover, perfusion with 0-2 mM auranofin also caused significant mucosal damage. Myochrysine had no effect on mucosal integrity. The reason for the difference in the effects of the two gold compounds is not readily apparent. Myochrysine may interact less readily with the enterocyte surface and have less access to the interior of the enterocytes because it is more polar and present in polymer form."'6 On the other hand the possibility that the injury is not an expression of gold toxicity but is caused by the structure of the carrier molecule cannot be excluded. We do not think, that taurocholate and lecithin in the auranofin solutions are responsible for these differences. Taurocholate (10 mM) by itself has no effect on intestinal water transport in man1952 or experimental animals2' and lecithin blocks any possible adverse effects by bile acids." '22 We are not aware of any studies of gastric or intestinal morphology in patients receiving auranofin.
The purpose of the experiments was to determine whether auranofin has an effect on intestinal water and electrolyte transport. The observations show one possible mechanism for diarrhoea in patients receiving the drug. Other potential effects of auranofin which might contribute to diarrhoea, such as effects on intestinal motility or effects of auranofin metabolites on intestinal function, remain to be explored. Similarly, the possible modification of these effects by gastric, biliary, and pancreatic secretions will need to be evaluated. As the intraluminal concentrations of the drug in patients receiving auranofin are not known, it is not certain that the concentrations used in these perfusion experiments resemble those in the human intestine. Because only 15 to 30% of auranofin is absorbed and as the compound is poorly water soluble, it is, however, likely that it reaches the colon in concentrations close to its solubility limits. If 0-2 mM auranofin can induce net fluid secretion in the colon, lower concentrations will be able to inhibit net water absorption. Under normal conditions about 2500 ml of fluid enter the human colon in a 24 hour period. 23 The colon reabsorbs 2300 ml, that is 92%. It takes only a reduction of the absorption rate from 92% to 84% to result in a fecal weight of 400 g, which would be perceived as diarrhoea. Thus, much lower colonic concentrations of auranofin will suffice to cause diarrhoea. Clinical observations also suggest that the diarrhoea is caused by a direct effect of auranofin on the intestinal mucosa: there is no correlation between serum gold levels and the presence of diarrhoea,24 diarrhoea and abdominal cramping are observed within three to four hours after ingestion of the drug24 and diarrhoea disappears with reduction of the dose or when the drug is administered in divided doses. 
